CRISPR Therapeutics AG (CRSP) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Nineteen firms give CRISPR Therapeutics an average “Moderate Buy” rating, with nine buys, two strong buys, seven holds and one sell. The average 12-month price target is $65.75.
• CASGEVY and the pipeline are gaining momentum: Third-quarter CASGEVY revenue rose 30% sequentially to $99 million, while CTX310 received FDA RMAT designations and upcoming clinical data could provide further catalysts.
• Losses and funding needs remain key risks: CRISPR reported a third-quarter loss of $1.15 per share and revenue of $12.67 million, both below expectations, while continued pipeline spending and substantial operating losses could limit near-term profitability.

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been given an average rating of "Moderate Buy" by the nineteen research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $65.75.

CRSP has been the subject of several recent analyst reports. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Thursday, October 15th. Citigroup reissued a "market outperform" rating on shares of CRISPR Therapeutics in a research report on Monday, September 28th. Needham & Company LLC restated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Finally, HC Wainwright reaffirmed a "buy" rating on shares of CRISPR Therapeutics in a research report on Friday, October 9th.

Insiders Place Their Bets

In other CRISPR Therapeutics news, Director Simeon George sold 14,514 shares of the firm's stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total value of $720,329.82. Following the sale, the director owned 15,486 shares of the company's stock, valued at $768,570.18. This trade represents a 48.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the completion of the transaction, the chief executive officer directly owned 311,899 shares in the company, valued at approximately $15,526,332.22. This represents a 13.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 93,558 shares of company stock worth $4,881,663 over the last quarter. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently modified their holdings of CRSP. Canal Insurance CO bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth approximately $1,670,000. Quantinno Capital Management LP increased its position in shares of CRISPR Therapeutics by 613.5% during the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company's stock valued at $2,283,000 after purchasing an additional 41,263 shares during the period. KBC Group NV raised its stake in shares of CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company's stock valued at $5,558,000 after purchasing an additional 113,997 shares in the last quarter. Raiffeisen Bank International AG acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at $1,127,000. Finally, Shah Wealth Advisors LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at $3,767,000. 69.20% of the stock is owned by institutional investors.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY momentum improved: The company reported $99 million in third-quarter CASGEVY revenue, up 30% sequentially and nearly sixfold from the prior-year quarter. The treatment also received expanded approvals for younger children in the U.K., United Arab Emirates and Bahrain. CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Pipeline regulatory progress: The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. Upcoming clinical data presentations for CTX310 and zugo-cel could provide additional catalysts, while enrollment has been completed in the Phase 2 CTX611 knee-replacement study. Business Update and Third Quarter Results
• Neutral Sentiment: Manufacturing leadership added: Siva Sakhamuri was appointed chief technical officer. His experience in biologics, vaccines, oligonucleotides, RNA therapies and lipid nanoparticles may support manufacturing and commercialization as CRISPR expands its product portfolio. Appointment of Siva Sakhamuri
• Negative Sentiment: Earnings missed expectations: CRISPR reported a third-quarter loss of $1.15 per share, worse than the roughly $1.04–$1.06 consensus. Reported revenue of $12.67 million also trailed the $14.75 million estimate in market reports, increasing concerns about near-term profitability. CRISPR Therapeutics Earnings Report
• Negative Sentiment: Funding risk remains: Despite CASGEVY’s growth, CRISPR continues to post substantial losses and relies heavily on its cash balance to finance an expensive clinical pipeline, limiting the immediate earnings benefit from commercialization.

CRISPR Therapeutics Stock Down 2.8%

CRSP opened at $49.99 on Tuesday. The business has a 50 day moving average price of $54.00 and a 200 day moving average price of $52.89. CRISPR Therapeutics has a twelve month low of $44.12 and a twelve month high of $64.74. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The firm has a market cap of $4.83 billion, a P/E ratio of -10.50 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.11). CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $12.67 million for the quarter, compared to analyst estimates of $14.75 million. Research analysts forecast that CRISPR Therapeutics will post -4.44 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company's research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.